Biocon launches generic drug Tacrolimus capsules in the US market

Biocon Ltd, an innovation-led global biopharmaceuticals company, on Monday said that it has launched Tacrolimus capsules in the US.

Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients. The drug reduces the body's ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

The launch of Tacrolimus capsules, following approval from the US Food and Drug Administration (USFDA) in November 2020, underscores Biocon's relentless pursuit of its mission to make affordable healthcare accessible.

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said: "The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients."

Biocon Limited, publicly listed in 2004, is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.